Quarterly ResultMay 7, 2026, 04:42 PM
Xenon Pharma Q1 Net Loss $(102.3)M; Raises $837.5M in Equity Offerings
AI Summary
Xenon Pharmaceuticals Inc. reported a net loss of $(102.3) million for the first quarter of 2026, a significant increase from the $(65.0) million loss in the prior year period, with no collaboration revenue compared to $7.5 million in Q1 2025. Research and development expenses rose substantially to $88.5 million. However, the company significantly bolstered its financial position by raising $837.5 million through equity offerings, bringing its total cash, cash equivalents, and marketable securities to $1.34 billion, which is expected to fund operations for at least the next 12 months.
Key Highlights
- Net proceeds from equity offerings totaled $837.5 million for the quarter.
- Net loss increased to $(102.3) million, up 57.3% from $(65.0) million in Q1 2025.
- Collaboration revenue was $0 in Q1 2026, down from $7.5 million in Q1 2025.
- Research and development expenses rose 44.6% to $88.5 million from $61.2 million.
- General and administrative expenses increased 25.1% to $23.8 million from $19.0 million.
- Cash, cash equivalents, and marketable securities reached $1.34 billion as of March 31, 2026.
- Accumulated deficit grew to $1.35 billion as of March 31, 2026.
- Azetukalner R&D costs were $47.1 million, up from $31.5 million in Q1 2025.